Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

EntreMed Files to Start China Arm of Phase II Ovarian Cancer Trial

publication date: Jan 14, 2014
EntreMed, a US-China pharma, filed a new drug clinical trial application for a China Phase II trial of ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC). The application will turn the on-going US Phase II trial into a global trial. OCCC will be the third indication for which ENMD-2076 is being tested in a US-China clinical trial, joining triple-negative breast cancer and advanced/metastatic soft tissue sarcoma. The company said its global trial will reduce approval time in China by three years. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital